(60 days)
No
The device description mentions a "defined algorithm that adjusts the generator output as a function of the electrical resistance of the tissue." While this is an algorithm, it is described as a fixed function based on electrical resistance, not a system that learns or adapts from data, which is characteristic of AI/ML. There are no mentions of AI, ML, deep learning, training data, or performance metrics typically associated with AI/ML models.
No.
The device is an electrosurgical tool used for ligation and division of vessels and tissues during surgical procedures, which is a surgical intervention rather than a therapeutic treatment in itself.
No
The device is described as a bipolar instrument intended for use in open surgical procedures for coagulation and sealing of vessels and tissues, which are therapeutic functions, not diagnostic.
No
The device description clearly states it is a "sterile, single use, hand-held electrosurgical device" and attaches to a generator with a cord and connector, indicating it is a physical hardware device. While it uses an algorithm from the generator, the core device itself is hardware.
Based on the provided text, the BiZact device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for use in open surgical procedures for ligation and division of vessels, tissue bundles, and lymphatics. This is a surgical intervention performed directly on the patient's body.
- Device Description: The description details a hand-held electrosurgical device that uses RF tissue fusion technology. This is a therapeutic device used to modify tissue within the body.
- Lack of IVD Characteristics: An IVD device is used to examine specimens (like blood, urine, or tissue samples) outside the body to provide information for diagnosis, monitoring, or screening. The BiZact device does not perform any such analysis of specimens.
The BiZact device is a surgical instrument used for therapeutic purposes during surgery, not for in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The BiZact™ device is a bipolar instrument intended for use in open surgical procedures where ligation and division of vessels, tissue bundles, and lymphatics is desired.
The tissue fusion function of the device can be used on vessels (arteries and veins) and lymphatics up to and including 3 mm diameter. The BiZact device is indicated for use in open general surgical procedures.
It is also indicated for adult and adolescent ENT procedures (12 years of age and above), including tonsillectomy for the ligation and division of vessels, tissue bundles and lymphatics 2-3 mm away from unintended thermally sensitive structures.
The BiZact™ device has not been shown to be effective for tubal sterilization or tubal coagulation for sterilization procedures. Do not use for these procedures.
Product codes (comma separated list FDA assigned to the subject device)
GEI
Device Description
The BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider is a sterile, single use, hand-held electrosurgical device that incorporates RF tissue fusion technology for a desired tissue effect when used with the ForceTriad Energy Platform (ForceTriad), the Valleylab™ LS10 LS Series Single Channel Vessel Sealing Generator (VLLS10GEN), or the Valleylab™ FT10 Energy Platform (VLFT10GEN) for ligation and division of vessels, tissue bundles, and lymphatics during open general surgical procedures.
The BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider attaches to a compatible electrosurgical generator with a 10-foot cord containing a proprietary connector. The generator can identify the BiZact™ device via the RFID tag embedded in the connector (VLLS10GEN and VLFT10GEN) or with a barcode on the connector (ForceTriad). The generator delivers energy to the device using a defined algorithm that adjusts the generator output as a function of the electrical resistance of the tissue. The combination of the BiZact instrument and the generator algorithm achieve complete and permanent tissue fusion.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
vessels, tissue bundles, lymphatics, tonsillectomy
Indicated Patient Age Range
adult and adolescent (12 years of age and above)
Intended User / Care Setting
open surgical procedures
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation results demonstrate that the BiZact Adolescent Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider performs as intended. The following summarizes testing conducted to establish safety and substantial equivalence:
- IEC 60601-1 Basic Electrical Safety
- IEC 60601-1-2 Electromagnetic Compatibility
- IEC 60601-2-2 Basic Safety for HF Equipment and HF Accessories
- ISO 10993-1 Biocompatibility
- Performance Testing Device Functionality
- Performance Testing - Bench Tissue - burst testing (renal artery and lymph)
- Performance Testing - In-vivo - acute (hemostasis, thermal spread) and chronic (hemostasis)
No design or specification changes are associated with expanded indication, therefore the previous performance testing listed above remains applicable.
A study of clinical literature for tonsillectomy procedures in adults and adolescents show that treatments in tonsillectomy considering risk factors such as bleeding, and anatomical measurements of the treatment area in adults and adolescents are very similar without creating additional risk concerns for using the BiZact device to perform ENT procedures in both populations.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with "ADMINISTRATION" written below in a smaller font.
November 6, 2018
Covidien, LLC Rebecca Clark Senior Regulatory Affairs Specialist 5920 Longbow Drive Boulder, CO 80301
Re: K182451
Trade/Device Name: BiZact Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical Cutting and Coagulation Device and Accessories Regulatory Class: Class II Product Code: GEI Dated: September 6, 2018 Received: September 7, 2018
Dear Rebecca Clark:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Srinivas Nandkumar -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose, and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K182451
Device Name
BiZact Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider
Indications for Use (Describe)
The BiZact device is a bipolar instrument intended for use in open surgical procedures where ligation of vessels, tissue bundles and lymphatics is desired.
The tissue fusion function of the device can be used on veins) and lymphatics up to and including 3mm diameter. The BiZact device is indicated for use in open general surgical procedures.
It is also indicated for adult and adolescent ENT procedures (12 years of age and above), including tonsillectomy, for the ligation and division of vessels, tissue bundles and lymphatics 2-3 mm away from unintended thermally sensitive structures.
The BiZact device has not been shown to be effective for tubal coagulation for sterilization procedures. Do not use for these procedures.
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/1 description: The image shows the logo for Covidien. The logo consists of a blue square with a lighter blue vertical line and a white rectangle in the center. To the right of the square is the word "COVIDIEN" in a dark blue sans-serif font.
510(k) Summary Date summary prepared: October 30, 2018
510(k) Submitter/Holder
Covidien 5920 Longbow Drive Boulder, CO 80301
Contact
Rebecca Clark Senior Regulatory Affairs Specialist Telephone: 303-581-6427 Fax: 303-516-8316 Email: rebecca.a.clark@medtronic.com
Name of Device
Trade Name: BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider Catalog Number: BZ4212A Common Name: Bipolar Vessel Sealing Device Classification Name: Electrosurgical cutting and coagulation device and accessories (21 CFR 878.4400, Class II, GEI)
Predicate Device Trade Name: BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider Catalog Number: BZ4212A Common Name: Bipolar Vessel Sealing Device 510(k) Number: K171066 (cleared June 8, 2017) Manufacturer: Covidien
Device Description
The BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider is a sterile, single use, hand-held electrosurgical device that incorporates RF tissue fusion technology for a desired tissue effect when used with the ForceTriad Energy Platform (ForceTriad), the Valleylab™ LS10 LS Series Single Channel Vessel Sealing Generator (VLLS10GEN), or the Valleylab™ FT10 Energy Platform (VLFT10GEN) for ligation and division of vessels, tissue bundles, and lymphatics during open general surgical procedures.
The BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider attaches to a compatible electrosurgical generator with a 10-foot cord containing a proprietary connector. The generator can identify the BiZact™ device via the RFID tag embedded in the connector (VLLS10GEN and VLFT10GEN) or with a barcode on the connector (ForceTriad). The generator delivers energy to the device using a defined algorithm that adjusts the generator output as a function of the electrical resistance of the tissue. The combination of the BiZact instrument and the generator algorithm achieve complete and permanent tissue fusion.
4
How provided
The BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider is provided sterile and is intended for single use. It is disposable and provided prescription only.
Image /page/4/Picture/3 description: The image shows a medical device inside of a clear plastic package. The device is white and gray and has a long, thin needle extending from the front. A blue tube is connected to the device. The device is held in place by a white cardboard cutout.
Provided as viewed in the image below.
Compatible Electrosurgical Generators
BZ4212A, BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider compatible with:
Code: FORCETRIAD | Code: VLLS10GEN | Code: VLFT10GEN |
---|---|---|
Force Triad Energy Platform | Valleylab™ LS10 Vessel | |
Sealing Generator | Valleylab™ FT10 Energy | |
Platform |
Patient Contacting Materials in BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider
Patient contacting materials included in the manufacture of the BiZact™ Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider (BZ4212A) include stainless steel, Polyphthalimide (PPA), ceramic, Ethylene-tetraflouroethylene, silicone, and PFTE lubricants.
Comparison of Technological Characteristics with the Predicate Device
BiZact Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider (BZ4212A) and is unchanged from the predicate device, as cleared under K171066, in terms of intended use, design, performance, and technological characteristics. The only difference is that the Indications for Use has been changed to include an adolescent population (12-21 years of age).
5
K182451 | |||
---|---|---|---|
CHARACTERISTIC | PROPOSED DEVICE | PREDICATE DEVICE | Comment |
BiZact (BZ4212A) | BiZact (BZ4212A) | ||
K182451 | K171066 | ||
Class Regulation | 878.44 | 878.44 | Same |
Class | II | II | Same |
Product Code | GEI | GEI | Same |
Indications for Use | The BiZact device is a | ||
bipolar instrument | |||
intended for use in | |||
open surgical | |||
procedures where | |||
ligation and division of | |||
vessels, tissue bundles, | |||
and lymphatics is | |||
desired. |
The tissue fusion
function of the device
can be used on
vessels(arteries and
veins) and lymphatics
up to and including 3
mm diameter. The
BiZact device is
indicated for use in
open general surgical
procedures.
It is also indicated for
adult and adolescent
ENT procedures (12
years of age and
above), including
tonsillectomy, for the
ligation and division of
vessels, tissue bundles
and lymphatics 2-3 mm
away from unintended
thermally sensitive
structures.
The BiZact device has
not been shown to be
effective for tubal
sterilization or tubal
coagulation for
sterilization procedures.
Do not use for these
procedures. | The BiZact device is a
bipolar instrument
intended for use in
open surgical
procedures where
ligation and division of
vessels, tissue bundles,
and lymphatics is
desired.
The tissue fusion
function of the device
can be used on
vessels(arteries and
veins) and lymphatics
up to and including 3
mm diameter. The
BiZact device is
indicated for use in
open general surgical
procedures.
It is also indicated for
adult ENT procedures,
including
tonsillectomy, for the
ligation and division of
vessels, tissue bundles
and lymphatics 2-3 mm
away from unintended
thermally sensitive
structures.
The BiZact device has
not been shown to be
effective for tubal
sterilization or tubal
coagulation for
sterilization procedures.
Do not use for these
procedures. | Expansion to include
adolescent in the
indication. |
| Contraindications | None | None | Same |
| Instrument Design | Pistol Grip | Pistol Grip | Same |
| K182451 | | | |
| Energy Type | Electrical (RF)bipolar energy | Electrical (RF) bipolar energy | Same |
| CHARACTERISTIC | PROPOSED DEVICE | PREDICATE DEVICE | Comment |
| | BiZact (BZ4212A) | BiZact (BZ4212A) | |
| Compatible Energy
Platform(s) and 510(k)s | Valleylab ForceTriad™ | Valleylab ForceTriad™ | Same |
| | (K102913) | (K102913) | |
| | Valleylab FT10 Energy
Platform, Valleylab
FX8 FX Series Energy
Platform(K181389) | Valleylab FT10 Energy
Platform, Valleylab
FX8 FX Series Energy
Platform(K181389) | Same |
| | ValleylabTM LS, LS
Series Single Channel
Vessel Sealing
Generator (K143654) | ValleylabTM LS, LS
Series Single Channel
Vessel Sealing
Generator (K143654) | Same |
| Energy Activation
(Generator) | Handswitch (All
compatible generators) | Handswitch (All
compatible generators) | Same |
| | Footswitch
(ForceTriad) (Valleylab
VLFT10) | Footswitch
(ForceTriad) (Valleylab
VLFT10) | Same |
| | | | |
| | | | |
| Hand-activated button
design | Single stage | Single Stage | Same |
| | | | |
| Proprietary Connector | Yes | Yes | Same |
| In-Line Activation | Yes | Yes | Same |
| Cutting Mechanism
Design | Integrated cutting blade | Integrated cutting blade | Same |
| | | | |
| Single Use | Yes | Yes | Same |
| Sterile | Yes | Yes | Same |
| Sterilization Method | EO | EO | Same |
| Vessel Size Range | Up to and including 3
mm | Up to and including 3
mm | Same |
| | | | |
6
Indications for Use
The BiZact™ device is a bipolar instrument intended for use in open surgical procedures where ligation and division of vessels, tissue bundles, and lymphatics is desired.
The tissue fusion function of the device can be used on vessels (arteries and veins) and lymphatics up to and including 3 mm diameter. The BiZact device is indicated for use in open general surgical procedures.
It is also indicated for adult and adolescent ENT procedures (12 years of age and above), including tonsillectomy for the ligation and division of vessels, tissue bundles and lymphatics 2-3 mm away from unintended thermally sensitive structures.
The BiZact™ device has not been shown to be effective for tubal sterilization or tubal coagulation for sterilization procedures. Do not use for these procedures.
7
Performance Summary
Verification and validation results demonstrate that the BiZact Adolescent Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider performs as intended. The following summarizes testing conducted to establish safety and substantial equivalence:
- IEC 60601-1 Basic Electrical Safety
- IEC 60601-1-2 Electromagnetic Compatibility ●
- IEC 60601-2-2 Basic Safety for HF Equipment and HF Accessories ●
- ISO 10993-1 Biocompatibility ●
- Performance Testing Device Functionality ●
- Performance Testing - Bench Tissue - burst testing (renal artery and lymph)
- . Performance Testing - In-vivo - acute (hemostasis, thermal spread) and chronic (hemostasis)
No design or specification changes are associated with expanded indication, therefore the previous performance testing listed above remains applicable.
Clinical Literature Summary
A study of clinical literature for tonsillectomy procedures in adults and adolescents show that treatments in tonsillectomy considering risk factors such as bleeding, and anatomical measurements of the treatment area in adults and adolescents are very similar without creating additional risk concerns for using the BiZact device to perform ENT procedures in both populations.
Conclusion on Substantial Equivalence
The proposed BiZact Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider (BZ4212A) for use in adolescents defined as (12-21 years of age in this submission) is substantially equivalent to the predicate BiZact Tonsillectomy Device Advanced Bipolar Tissue Sealer/Divider (BZ4212A) for use in adults defined as (22+ years of age). Supporting clinical literature attached to this submission shows that inclusion of adolescents in the indications for this device do not raise new questions of safety or efficacy.
All performance and design specifications remain the same as for the previously cleared design. The subject device is substantially equivalent to the 510(k) cleared predicate device.